arrow
Return

ILOBONE: A phase I/IIa randomized controlled trial to assess the safety and feasibility of local iloprost therapy for enhancing proximal humerus fracture healing- a pilot study design

delete2025-05-22
delete0
delete
OA
AI
H
Hisham Elazaly
I
Ioanna Maria Dimitriou
T
Tazio Maleitzke
M
Michael Dahne
V
Vera Jaecker
S
Sven Maerdian
S
Sascha Tafelski
T
Torsten Diekhoff
T
Tobias Lindner
D
Doruk Akgün
M
Mielke, Anna-Maria
A
Alp Paksoy
D
Dominik Adl Amini
E
Elisa Marie Planatscher
V
Vincent J. Leopold
S
Susana González-Khatib
K
Koehli, Paul Christoph
M
Marcel Niemann
A
Alexander Hildebrandt
S
Stephan Oehme
Y
Yannick Palmowski
M
Melissa Paraskevaidis
L
Lukas Schönnagel
S
Sebastian Braun
M
Matthias Pumberger
S
Sebastian Hardt
S
Sigmar Stricker
L
Levent Akyüz
G
Gerald Grütz
S
Stefan J. Schaller
L
Luis Lauterbach
M
Maximilian Volcksdorff
L
Lukas Mödl
M
Martin Textor
M
Melanie Ort
S
Simon Reinke
U
Ulrich Stöckle
C
Carsten Perka
G
Georg N. Duda
K
Katharina Schmidt-Bleek
S
Sven Geißler
T
Tobias Winkler *
DOI:10.1186/s13018-025-05865-2delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
BackgroundProximal humerus fractures (PHFs) are the third most common fractures in elderly patients. Over 70% of PHFs in patients aged over 60 are displaced fractures, often necessitating surgical treatment. However, osteosynthesis is associated with a high rate of complications, highlighting the urgent need for additional therapeutic approaches to enhance bone healing and prevent osteonecrosis. This study evaluates the safety, feasibility and potential efficacy of local prostacyclin (iloprost) to improve bone healing in patients with PHFs.MethodsThirty eligible patients will be randomized into one of three groups at a 1:1:1 ratio. All patients will receive angular stable locking plate fixation. Two treatment groups will receive an additional single dose of local iloprost through a 24-hour infusion postoperatively (group 1: low dose; group 2: high dose), while the control group will only receive the osteosynthesis. Patients will be monitored for 52 weeks. The primary endpoint is safety, with secondary endpoints including the preservation of the screw tip apex distance as an indicator of fracture healing, head shaft angle, necrosis rate, and patient-related outcome measures.DiscussionThe Ilobone study aims to provide data on the potential for biological augmentation of osteosynthesis procedures in PHFs, prone to healing challenges and complications.Trial registrationThe trial is registered with ClinicalTrial.gov (NCT04543682), registered 02 Sep. 2020, https://clinicaltrials.gov/show/NCT04543682 and the German Clinical Trials Registry (DRKS00027081), registered 10 Nov. 2021 https://drks.de/search/de/trial/DRKS00027081.
Keywords:
Proximal humerus fracture
Bone healing
Fracture repair
Iloprost
Ilomedin
PHILOS

Journal

Journal of Orthopaedic Surgery and Research cover
Journal of Orthopaedic Surgery and Research
IF:
2.8
Papers:
1.5K
Citations:
1.3W

Organization

U
Univ Copenhagen
Scholars:
3.1K
Papers: 1.5K
Citations: 707
C
Charite Univ Med Berlin
Scholars:
958
Papers: 576
Citations: 165
F
Freie Univ
Scholars:
45
Papers: 20
Citations: 5
H
Humboldt Univ
Scholars:
1.4K
Papers: 621
Citations: 206
researcher View more organizations